Showing 3007 results
-
Press release /Cosentyx® (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial¹Approval marks 11th US indication for Cosentyx, building on…
-
Press release /If approved, Cosentyx® (secukinumab) will become the only IL-17A inhibitor for adolescents with moderate to severe HS in Europe1,2HS affects as many as one in 100 people worldwide,3 with more…
-
Press release /RemIND data show clinically meaningful responses through Week 52 across three most prevalent CIndU subtypes, including after switching from placebo at Week 241Twice as many Rhapsido-treated patients…
-
Press release /Patients continuing ianalumab saw further improvement in systemic disease activity through Week 108, with no new safety findings1 Nearly two-thirds of patients on continuous ianalumab reached low…
-
Press release /Novartis retains first place ranking among 20 sector peers for efforts to improve access to medicinesFirst company to achieve No. 1 rank across all Technical Areas since Index began in 2008,…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 301
- › Next page